Antibodies are an essential immune system component B-cells produce to neutralize pathogens such as bacteria, viruses, and toxins. With the development of antibody engineering services, scientists have been able to modify the structure and function of antibodies to create novel therapeutics with[…]
Read MoreAn Antibody Engineering Service against tumor necrosis factor-alpha (TNF-α), like infliximab, is an attractive therapeutic approach to treat ocular surface diseases. TNF-α is a pleiotropic cytokine with an essential contribution to the pathogenesis of inflammation angiogenesis and collagenolysis. An individual intraperitoneal dose[…]
Read MoreThe serious acute respiratory syndrome covid 2 is the etiological agent of the covid induced disease 19 that emerged in China in late 2019 and caused a global pandemic. SARS-CoV-2 belongs to the subgenus Sarbecovirus together with SARS-CoV that emerged in 2002[…]
Read MoreUnderstanding the immune memory and tracking variant immunity to the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is vital for improving the continuous diagnosis and enhancing treatment in form of vaccines for any future outbreaks. Monitoring the variant immunity for SARS-CoV-2 spike[…]
Read MoreThe very first monoclonal antibody approved by the U.S. FDA (Food and Drug Administration) in 1997 ushered a new era in therapeutic applications for patients. A clinical breakthrough was acknowledged in the 1990s when there was the successful development of a humanized[…]
Read MoreThe progress in engineering and clinical development has been remarkable in the development of Therapeutic Antibody for 40 years, with the work done by Kohler and Milstein. The US FDA has led approval to the 21 antibodies for cancer immunotherapy. The approved[…]
Read MoreTreatment of diseases arose with the concept of antibodies back in the 1890s, by Emil Adolf von Behring. In the further 1960s, there were structural characteristics describers, forward marking discovery of Production Methods Of Monoclonal Antibodies (mAbs). The first mAb, muromonab-CD3, was[…]
Read MoreGolimumab has been principally targeting and neutralizing TNF proving itself as a valuable human anti-tumor necrosis factor (TNF) monoclonal antibody, actively preventing inflammation and destruction of cartilage and bone. Golimumab, Monoclonal Antibody Production, is largely represented by the biological community. 1. Sequential[…]
Read MoreAt GeNext Genomics, we are highly proud to serve the industry with the ability to cater for clients with antibody engineering services. These constitute each format, from the antibody fragments to the humanized antibodies. scFv/Fab scFV/Fab construction is the first and foremost[…]
Read More